ARCA biopharma (Nasdaq:ABIO) - Aandelenkoers, Nieuws & Analyse

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

ABIO Overzicht aandelen

A clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Meer informatie

ABIO fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Risicoanalyse

De winst is de afgelopen 5 jaar met 2.1% per jaar gedaald

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Heeft geen betekenisvolle marktkapitalisatie ( $51M )

Volatiele aandelenkoers in de afgelopen 3 maanden

ARCA biopharma, Inc. Concurrenten

MediciNova

NasdaqGM:MNOV

US$112.8m

Eagle Pharmaceuticals

OTCPK:EGRX

US$10.0m

Intensity Therapeutics

NasdaqCM:INTS

US$39.3m

Burning Rock Biotech

NasdaqGM:BNR

US$62.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor ARCA biopharma
Historische aandelenkoersen
Huidige aandelenkoers	US$2.50
52 Week Hoogtepunt	US$4.49
52 Week Laag	US$1.56
Bèta	0.89
11 maand verandering	-16.67%
3 maanden verandering	-32.43%
1 Jaar Verandering	21.95%
33 jaar verandering	-19.87%
5 jaar verandering	-52.11%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth

Apr 04

Recent updates

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Jul 15

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Mar 30

Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19

Dec 15

We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth

Dec 15

ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment

Nov 24

ARCA biopharma reports Q3 results

Nov 02

Rendement voor aandeelhouders

	ABIO	US Biotechs	US Markt
7D	-36.2%	-0.8%	0.4%
1Y	22.0%	12.9%	32.3%

Rendement versus industrie: ABIO overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 12.9 % opleverde.

Rendement versus markt: ABIO kwam overeen met de US markt, die het afgelopen jaar een rendement opleverde van 32.3 %.

Prijsvolatiliteit

Is ABIO's price volatile compared to industry and market?
ABIO volatility
ABIO Average Weekly Movement	12.9%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van ABIO is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 13% ) van ABIO is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	3	Tom Keuer	www.arcabio.com

ARCA biopharma, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van ARCA biopharma zich tot de beurswaarde?
ABIO fundamentele statistieken
Marktkapitalisatie	US$50.63m
Inkomsten(TTM)	-US$7.20m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-5.0x

Koers/Winstverhouding

Is ABIO overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ABIO resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$7.20m
Inkomsten	-US$7.20m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.50
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde ABIO op de lange termijn?

Bekijk historische prestaties en vergelijking

This company is no longer active

ABIO Overzicht aandelen

Risicoanalyse

ARCA biopharma, Inc. Concurrenten

NasdaqGM:MNOV

US$112.8m

OTCPK:EGRX

US$10.0m

NasdaqCM:INTS

US$39.3m

NasdaqGM:BNR

US$62.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Oruka Therapeutics entered into a definitive agreement to acquire ARCA biopharma, Inc. (NasdaqCM:ABIO) for approximately $180 million in a reverse merger transaction.

Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth

Oruka Therapeutics entered into a definitive agreement to acquire ARCA biopharma, Inc. (NasdaqCM:ABIO) in a reverse merger transaction.

New major risk - Share price stability

Arca Biopharma, Inc. Announces Executive Changes

ARCA biopharma, Inc., Annual General Meeting, Jan 30, 2024

Recent updates

Oruka Therapeutics entered into a definitive agreement to acquire ARCA biopharma, Inc. (NasdaqCM:ABIO) for approximately $180 million in a reverse merger transaction.

Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth

Oruka Therapeutics entered into a definitive agreement to acquire ARCA biopharma, Inc. (NasdaqCM:ABIO) in a reverse merger transaction.

New major risk - Share price stability

Arca Biopharma, Inc. Announces Executive Changes

ARCA biopharma, Inc., Annual General Meeting, Jan 30, 2024

ARCA biopharma, Inc. Announces Departure of Christopher D. Ozeroff as Senior Vice President and General Counsel

ARCA biopharma, Inc. Appoints James Flynn to Board of Directors

Insufficient new directors

ARCA biopharma, Inc., Annual General Meeting, Dec 15, 2022

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

ARCA Biopharma, Inc. Appoints Jacob Ma-Weaver Has Joined Its Board of Directors

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

Insufficient new directors

ARCA biopharma Establishes Special Committee of the Board of Directors

ARCA biopharma, Inc. Announces Results for ASPEN-COVID-19 Phase 2b Clinical Trial

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

ARCA biopharma, Inc. Announces Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Senior VP recently bought US$113k worth of stock

ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

ARCA biopharma, Inc. Provides Update on Aspen-Covid-19 Phase 2B Clinical Trial

Chief Accounting Officer & VP of Finance has left the company

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

New 90-day low: US$3.98

New 90-day high: US$4.93

New 90-day high: US$4.55

ARCA biopharma, Inc. Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19

Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19

We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth

ARCA biopharma, Inc. Announces AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation

ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment

New 90-day low: US$3.81

ARCA biopharma reports Q3 results

New 90-day low: US$4.03

ARCA biopharma, Inc. Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19

ARCA biopharma, Inc. Announces Promotion of Debra Marshall to Chief Medical Officer

New 90-day low: US$4.18

ARCA biopharma, Inc. Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19

New 90-day low - US$5.34

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

ARCA biopharma, Inc. Samenvatting

0.0x

-5.0x

Inkomsten en omzet